CDC25 dual-speci®city phosphatases are essential regulators that activate cyclin-dependent kinases (CDKs) at critical stages of the cell cycle. In human cells, CDC25A and C are involved in the control of G1/S and G2/M respectively, whereas CDC25B is proposed to act both in S phase and G2/M. Evidence for an interaction between CDC25 phosphatases and members of the 14-3-3 protein family has been obtained in vitro and in vivo in several organisms. On the basis of the work performed with CDC25C, it has been proposed that phosphorylation is required to mediate the interaction with 14-3-3. Here we have examined the molecular basis of the interaction between CDC25B phosphatases and 14-3-3 proteins. We show that in the two-hybrid assay all three splice variants of CDC25B interact similarly and strongly with 14-3-3Z, b and z proteins, but poorly with e and y. In vitro, CDC25B interacts at a low level with 14-3-3b, e, z, Z, and y isoforms. This interaction is not increased upon phosphorylation of CDC25B by CHK1 and is not abolished by dephosphorylation. In contrast, a speci®c, strong interaction between CDC25B and 14-3-3z and Z isoforms is revealed by a deletion of 288 residues in the amino-terminal region of CDC25B. This interaction requires the integrity of Ser 323, although it is independent of phosphorylation. Thus, interaction between 14-3-3 proteins and CDC25B is regulated in a manner that is dierent from that with CDC25C. We propose that, in addition to a low anity binding site that is available for all 14-3-3 isoforms, post-translational modi®cation of CDC25B in vivo exposes a highanity binding site that is speci®c for the z and Z14-3-3 isoforms.
Introduction
The eukaryotic cell cycle is controlled by a family of protein kinases called CDK (for cyclin-dependent kinases), whose activation is regulated by their association with regulatory subunits and through cycles of phosphorylation and dephosphorylation (Nigg, 1995) . For instance, the CDC2 (CDK1) protein kinase, in association with a cyclin B regulatory subunit, also known as MPF, controls the major reorganisation events that lead the cell to enter mitosis. The activity of this enzyme is tightly regulated (Russell and Nurse, 1986) by the WEE1 and CDC25 gene products that are a tyrosine kinase and phosphatase respectively. During interphase, WEE1p inhibits the activity of CDC2 protein kinase by phosphorylation of a critical tyrosine residue (Tyr15 in S. pombe CDC2). Conversely, dephosphorylation of the same residue by CDC25p activates the CDC2 protein kinase at the G2/M transition (Gautier et al., 1991) . In higher eukaryotic species, an additional site phosphorylated by the myt1 kinase is located at threonine 14 (Mueller et al., 1995) , and both residues are dephosphorylated by the CDC25 dual speci®city phosphatase.
In human, three CDC25 genes have been identi®ed (Galaktionov and Beach, 1991; Nagata et al., 1991; Sadhu et al., 1990) . The corresponding gene products share a high degree of identity in their carboxyterminal catalytic domain, which is highly evolutionarily conserved. They are more divergent in their aminoterminal half, which probably encompasses regulatory domains that are likely to specify their substrates, their partners and the mode of regulation of their activity. CDC25C regulates entry into mitosis by upregulating the activity of CDC2-cyclinB at the G2/M transition (Sadhu et al., 1990 ). CDC25A appears to be involved at the G1/S transition, where it controls the dephosphorylation of the CDK2-cyclinE protein kinase (Jinno et al., 1994) . The role of CDC25B has not yet been fully deciphered. Contradictory experimental data indicate a role for CDC25B in the progression into S phase (Garner-Hamrick and Fisher, 1998) , into G2-phase (Lammer et al., 1998) and in the regulation of the centrosomal nucleating activity (Gabrielli et al., 1996) . This apparent controversy may re¯ect the fact that sub-populations of CDC25B may perform subtly dierent functions at dierent stages of the cell cycle or/and in speci®c subcellular compartments. In favour of such hypothesis is the discovery of at least three splice variants of CDC25B that display dierences in their biochemical properties (Baldin et al., 1997 and unpublished results) .
CDC2-cyclin B is responsible for producing the highly phosphorylated forms of CDC25C observed during mitosis. Reciprocal interactions between CDC2-cyclinB and CDC25C create an auto-ampli®cation loop that sustains CDC2 and CDC25 activities to drive the cell into mitosis . Conversely, phosphatase 2A is proposed to be involved in a negative regulation of CDC25C activity . A similar mechanism of activation has also been described for CDC25A with the CDK2-cyclinE complex at the G1/S transition (Blomberg and Homann, 1999; Descombes and Nigg, 1998; Homan et al., 1994; Kumagai and Dunphy, 1996) .
Other kinases negatively regulate CDC25. The interphasic C-TAK1 (for Cdc Twenty-®ve Associated Kinase) prevents precocious activation of CDC25 (Peng et al., 1998; Peng et al., 1997) . Following various genomic injuries, additional checkpoint kinases, CHK1 and CHK2, further restrain CDC25 activity to prevent deleterious entry into mitosis (Furnari et al., 1997; Matsuoka et al., 1998; Sanchez et al., 1997) . Both types of inactivating kinases act through a common mechanism, generating a phosphoserine at residue 216 that acts as a docking site for 14-3-3 proteins.
The 14-3-3 proteins (seven isoforms in mammals, named b, e, z, Z, t, s, y) are highly conserved, acidic chaperones that assemble to form homo-and heterodimers that are able to interact with various cellular proteins (Aitken, 1995; Jones et al., 1995) . Their biological role is still poorly understood but results of recent studies performed in various models converge to suggest that they act as adapter molecules, establishing functional interaction between signal transduction pathways and the cell cycle control machinery (Baldin, 1999) .
An association between 14-3-3 and CDC25C was revealed in G1, S and G2 but never in mitosis in synchronised HeLa cells (Peng et al., 1997) . Mutation of Ser-216 in CDC25C abolishes the interaction with 14-3-3 proteins, both in vitro and in vivo (Sanchez et al., 1997) . This site lies in the middle of a potential recognition motif for 14-3-3 binding: RSP 216 SMP and is phosphorylated by the C-TAK1, CHK1 and CHK2 kinases (Matsuoka et al., 1998; Peng et al., 1997 Peng et al., , 1998 Sanchez et al., 1997) . A similar dependency on the phosphorylation of Ser-287, which is equivalent to Serine-216 in human, was shown for the interaction of Xenopus CDC25 with 14-3-3 e and z, (Kumagai et al., 1998b) . The current model is that CHK1 and CHK2 maintain CDC25C in an active form and/or prevent it from interacting with its substrate during the checkpoint response to DNA damage or replication abnormalities. In contrast, the C-TAK1 kinase is thought to be responsible for keeping CDC25C inactive throughout interphase (Lopez-Girona et al., 1999; Matsuoka et al., 1998; Peng et al., 1998; Walworth and Bernards, 1996) . Finally, recent publications show that, in Xenopus cells, interaction with 14-3-3 e isoform provokes the silencing of CDC25C NLS, leading to its cytoplasmic retention and so preventing nuclear activity of MPF (KumagaõÈ and Dunphy, 1999) and that, in mammals, cytoplasmic localisation of CDC25C requires an intact 14-3-3 binding site (Dalal et al., 1999) .
In higher eukaryotes, cell cycle progression and G2/ M transition also depend on CDC25B activity. It is highly probable that CDC25B and CDC25C share common substrates and regulatory mechanisms. For instance, CHK1 binds to and phosphorylates CDC25B phosphatase in vitro (Sanchez et al., 1997) . Two 14-3-3 isoforms, b and e, were shown to interact with the CDC25A and B phosphatases in the two hybrid system (Conklin et al., 1995) . However, the identity of the phosphorylated site has not been clari®ed, although residue Ser-216 is conserved among the three human CDC25s. Whether phosphorylation of CDC25B is required for the interaction with 14-3-3 has still to be Figure 1 CDC25B interaction with 14-3-3 in two-hybrid assay. (a) Interaction between CDC25B3 and members of the 14-3-3 family. GAL4BD-CDC25B3 fusion proteins and GAL4AD-14-3-3 isoforms fusion proteins interact in budding yeast cells, reconstituting functional GAL4 transcriptional activator. The expression of HIS3 from the GAL4 promoter allows the his3 host cell to grow on media lacking histidine in the absence or presence of increasing concentration of 3 AT (amino-triazol). In the right panel, the N-ter CDC25B3 construct is restricted to the ®rst 254 residues of the coding sequence. Positive control (+) is a strain transformed with GAL4BD-Braf and GAL4AD-14-3-3z. A strain transformed with GAL4BD-CDC25B3 and Gal4AD alone is used as negative control (7). (b) Schematic drawing of the CDC25B3 sequence showing the position of the two domains that are alternatively spliced in the CDC25B variants (grey boxes) and the three putative 14-3-3 binding domains CDC25B and 14-3-3 interaction V Mils et al proven. Likewise, whether CDC25B variants interact with speci®c 14-3-3 isoforms, and whether CDC25B and C share the same 14-3-3 partnerships, are questions that remain to be examined. These points are investigated in detail in this article. We provide evidence for the existence of CDC25B regulatory mechanisms that are distinct from those described for CDC25C.
Results

CDC25B phosphatases interact with 14-3-3 proteins
A two-hybrid assay in budding yeast was used to investigate whether CDC25B and its splice variants (B1, B2 and B3) (Baldin et al., 1997) could interact with members of the 14-3-3 family. The three CDC25B splice variants were cloned in frame with the GAL4 DNA binding domain, whereas 14-3-3 cDNAs were fused to the GAL4 DNA activating domain. The HIS3 reporter gene was used to monitor the interactiondependent growth of yeast cells. All three CDC25B variants interacted similarly with the ®ve 14-3-3 isoforms tested (not shown); thus only the data concerning CDC25B3 will be presented. As shown in Figure 1 , the strongest interaction was observed with the z, b and Z isoforms for which histidine prototrophy persisted in the presence of high concentrations of 3AT. Interaction obtained with the y isoforms was low and even barely detectable in the case of e. Additional experiments performed using C-terminal truncated constructs indicated that the N-terminal regions of CDC25B (residues 1 ± 254) do not elicit a signi®cant interaction with 14-3-3 proteins ( Figure 1a , right panels). Taken together, these results indicate that (i) three 14-3-3 isoforms interact strongly with CDC25B in vivo, (ii) there is no apparent speci®city of interaction with a particular CDC25B variant, and that (iii) interaction between 14-3-3 and CDC25B requires the integrity of regions that are located downstream of the N-terminal regulatory domain of the phosphatase. Thus, we speculate that the C-terminal catalytic domain of CDC25B contains the most stringent site for 14-3-3 binding. In support of this idea, sequence analysis of CDC25B reveals at least three putative 14-3-3 binding sites, one of which is located in the Cterminal moiety, the two others are also located in conserved regions between the three CDC25B splice variants (Figure 1b) . Alignment between CDC25C and CDC25B indicates that the former RSPSMP motif contains the homologue of CDC25C Ser-216 and might therefore be involved in 14-3-3 binding.
In vitro interaction between CDC25B and 14-3-3 isoforms
We next wished to investigate in detail the in vitro interaction between CDC25B and a panel of known members of the 14-3-3 family. MBP fusion proteins with the e, z, Z, y and b 14-3-3 isoforms were constructed or generously provided (see Materials and methods section) and produced in E. coli. Interaction with 35 S-labeled, in vitro translated CDC25B3 was assayed after incubation of this recombinant protein with the MBP-14-3-3 fusion proteins followed by anity chromatography on amylose beads. MBP alone was used as control. As shown in Figure 2a , binding of CDC25B was detected with all 14-3-3 variants tested. However, albeit speci®c, this interaction was weak and less than 10% of the CDC25B input was usually recovered on the bound material (not shown). The interaction level was in the range of 2 ± 3-fold the binding level observed with MBP alone and required Figure 2 In vitro interaction between CDC25B and 14-3-3 isoforms.
35
S-methionine labelled in vitro translated CDC25B3 (a) or DN310-CDC25B (b) was incubated in the presence of the indicated recombinant MBP-14-3-3 proteins or with MBP alone. Amylose beads were used to recover CDC25B bound to 14-3-3 and were subjected to SDS ± PAGE prior to autoradiography. The interaction level was quanti®ed and is expressed in arbitrary units (a.u.) as a function of the control interaction measured with MBP alone. Exposure duration in (a) is longer than in (b) to allow the detection of weak interaction level Figure 3 Interaction between 14-3-3z, Z and e with truncated forms of CDC25B3. (a) The set of CDC25B3 mutant proteins used in the following experiment. The grey zone indicates a stretch of His that has been added at the N-terminus of all truncated forms of CDC25B. The three putative phosphorylated serine residues in 14-3-3 binding sites are also indicated. (b) In vitro translated wild-type and truncated forms of CDC25B were incubated in the presence of recombinant 14-3-3 proteins isoforms. Bound material was recovered on amylose beads subjected to electrophoresis and autoradiography. Quanti®cation was performed on a Molecular Dynamics STORM840 imager and is expressed in arbitrary units Oncogene CDC25B and 14-3-3 interaction V Mils et al longer exposure time of the gel to be detected. We noticed that the dierences in anity that were evidenced between CDC25B and the 14-3-3 isoforms in the two-hybrid assay were not reproduced in vitro. This result suggests that high anity 14-3-3 binding site might be buried in the recombinant CDC25B produced in vitro and that post-translational modi®ca-tions might be required to unmask it.
Evidence for a specific interaction between CDC25B and 14-3-3 z and Z A number of lines of evidence indicate that the aminoterminal region of CDC25B has a cis-inhibitory in¯uence on its catalytic activity that is lifted upon deletion of this region of the phosphatase (Xu and Burke, 1996 ; and our own unpublished results). This phenomenon is a common feature of phosphatases which, in the inactive state, might adopt a closed conformation through intramolecular inhibitory interactions (Weiss and Schlessinger, 1998) . Post-translational modi®cation of CDC25B, such as phosphorylation or interaction with partners, might trigger conformational changes and allow the enzyme to be activated. Thus, deletion of the N-terminal half of the protein is able to mimic these changes, at least partially. We hypothesized that the conformation of that region of CDC25B could also sterically modulate binding to 14-3-3 proteins. We therefore examined the interaction between N-terminal truncated form (DN310) of CDC25B and MBP-14-3-3 recombinant fusion proteins. As shown by comparison of the binding level (Figure 2a,b) , the interaction of CDC25B with 14-3-3 e, and y was weak with the mutant and the full length CDC25B protein and even decreased in the case of e when the truncated CDC25B was used. In contrast, the interaction of 14-3-3 z, Z and to a lower extent b with DN310-CDC25B was strongly enhanced. Thus, 14-3-3 proteins can be classi®ed into two groups as regards their interaction with CDC25B; one set of proteins, whose interaction with wild-type CDC25B is speci®c but low, and a second set (z and Z, and possibly b), whose interaction is similarly low, but is strongly enhanced upon deletion of the amino-terminal domain.
Mapping of the CDC25B-14-3-3 interaction
These results prompted us to characterize in more detail the regions of CDC25B that are required for the interaction with 14-3-3z and Z. To investigate this question, we made use of the set of N-terminal CDC25B deletion mutants that is pictured in Figure  3a . Interaction between the 14-3-3z and Z recombinant proteins and these mutant CDC25B proteins was examined as described above and quanti®ed. The 14-3-3e isoform was also examined as a control. As shown in Figure 3b , progressive removal of the N-terminal Figure 4 Interaction between CDC25B and 14-3-3Z is not dependent on phosphorylation. (a) Wild type CDC25B3 or S323G-CDC25B3 mutant was incubated (+) or not (7) with recombinant CHK1 in the presence of ATPgP 32 , as described in the Materials and methods section. The reaction mix was subjected to SDS ± PAGE electrophoresis then imaged using a STORM840 imager (Molecular Dynamics). The acrylamide concentration used in the right panel allows a better separation of two phosphorylated forms of CDC25B. (b) Kinetic of phosphorylation of CDC25B3 and S323G-CDC25B3 by CHK1 performed as in (a). The incorporation of 32 P was normalized to the number of moles of CDC25B or S323G-CDC25B proteins present in the assay. (c) The set of amino-terminal deletion mutants of CDC25B3 presented in Figure 3 was phosphorylated by CHK1 as in (a). Phosphorylation was normalized to the number of moles of CDC25B substrate and is expressed as a percentage of the incorporation in the wild-type CDC25B. (d) Wild-type, full-length CDC25B or DN242-CDC25B was incubated with or without CHK1 kinase as in (a), then assayed for interaction with the 14-3-3Z isoform. The inserts show the autoradiography with the shift induced by CHK1 phosphorylation CDC25B and 14-3-3 interaction V Mils et al domain of CDC25B led to an increase in the interaction that reached a maximum after deletion of the ®rst 310 residues. In contrast, a reduction rather than an enhancement was observed between 14-3-3e and CDC25B in the case of all the truncated forms tested. Interestingly, the interaction between 14-3-3z and Z, and CDC25B was abolished when a further 13 residues were deleted (mutant DN323-CDC25B).
At this stage, we could conclude that a speci®c and strong interaction between CDC25B and 14-3-3 z or Z requires: (i) a conformational modi®cation of the amino-terminal domain that is mimicked by the deletion of that domain and; (ii) the integrity of residues 310 ± 323, a region that encompasses the third 14-3-3 binding motif that contains the CDC25C S216 homologue.
Similar experiments were performed with the 14-3-3b isoform but the results obtained were more ambiguous. In fact, enhanced interaction with truncated CDC25B was only observed with the DN310 mutant. Thus, the interaction between 14-3-3b and CDC25B may need additional requirements that are not ful®lled in our experimental conditions.
Interaction between CDC25B and 14-3-3Z is independent of phosphorylation In gamma irradiated cells, G2 delay depends on the phosphorylation of S216 on CDC25C by the CHK1 kinase and its subsequent association with 14-3-3 proteins (Sanchez et al., 1997) . We therefore examined the eect of CDC25B phosphorylation by CHK1 on its ability to bind 14-3-3Z. With this aim, recombinant CHK1 kinase was produced in E. coli and used to phosphorylate in vitro translated wild-type or mutant forms of CDC25B. CDC25B was phosphorylated by CHK1 ( Figure 4a , left panel) but this phosphorylation did not promote the association with 14-3-3Z which remained low (Figure 4d ). As shown in Figure 4c , a DN288 deletion largely abolished phosphorylation by CHK1 although one of the putative sites was still present. In order to address the question of the dependency of the interaction on CHK1 phosphorylation, it was therefore necessary to perform the subsequent assay using the DN242 mutant. Although this DN242 mutant remained a good CHK1 substrate (Figure 4c ), its phosphorylation did not enhance the interaction with 14-3-3Z (Figure 4d) .
Thus, we considered the possibility that a contaminating kinase present in the reticulocyte lysate could phosphorylate CDC25B. In order to examine this issue, we examined the eects of a lambda phosphatase treatment of CDC25B prior to the interaction assay with 14-3-3Z. Phosphorylation occurring in the reticulocyte lysate was abolished by this treatment as detected by the disappearance of a minor low mobility form of CDC25B that is detected upon appropriate SDS ± PAGE conditions (Figure 5a left panel, arrow) and by a decrease of about 85% of the phosphorylation level of CDC25B (Figure 5a, right panel) . However, as shown in Figure 5b , such treatment had no detectable eect on the binding of the two isoforms of 14-3-3 neither to DN288-CDC25B nor to wild-type CDC25B. Phosphorylation occurring in the lysate is likely to concern domain 1 ± 288 because the shift of the protein is not visible with DN288. It is also possible that because of its smaller size the shift does not occur or is not detected on the mutant whereas it is actually phosphorylated.
We could therefore conclude from these experiments that the enhancement of the binding between the truncated form of CDC25B and speci®c 14-3-3 isoforms is not due to an artefactual phosphorylation event but, rather, to a conformational change (see discussion). Furthermore, these results demonstrate In vitro translated wild type of DN288-CDC25B were incubated in the presence of lambda phosphatase as in (a), then assayed for the interaction with MBP or MBP 14-3-3 as in the previous ®gures. Bound material was recovered on amylose beads and electrophoresed. The level of interaction was quanti®ed using a STORM840 imager. (c) Wildtype, full-length CDC25B or DN242-CDC25B were mutated or not on Serine 323, which was replaced by glycine. In vitrotranslated CDC25B proteins were assayed for the interaction with 14-3-3Z isoform Oncogene CDC25B and 14-3-3 interaction V Mils et al that strong 14-3-3 binding in the 310 ± 323 region does not require any phosphorylation on CDC25B.
Serine 323 is required for 14-3-3 binding to CDC25B in vitro and in vivo To con®rm that phosphorylation of S323 is unnecessary for 14-3-3 binding in the 310-323 region, we also examined the consequence of the mutation of serine 323 to a non phosphorylatable residue. Figure 4a shows that point mutation of Ser-323, did not impair CDC25B phosphorylation by CHK1. In addition, a kinetic of phosphorylation experiment further con®rmed that the S323-CDC25B mutant is phosphorylated as eciently as the wild type CDC25B by CHK1 (Figure 4b) . Thus, although CDC25B is phosphorylated by CHK1, this phosphorylation does not occur on the conserved Ser-323 residue but on a dierent, as yet unidenti®ed, site. We then compared the interaction of 14-3-3 isoforms with wild-type or mutant CDC25B (Figure 5c ). In the case of fulllength CDC25B, a Ser-323-Gly mutation had no detectable eect on the weak interaction with 14-3-3Z isoform as with e, z (not shown). In contrast, the intermediate level interaction between the DN242-S323G-CDC25B mutant and 14-3-3Z isoform was fully abolished. The lack of interaction between DN242-S323-CDC25B and 14-3-3Z indicate that upon removal of the amino-terminal domain of CDC25B, serine 323 becomes essential for the interaction. Thus, although the phosphorylation of S323 is not required for binding of 14-3-3 in the 310 ± 323 region, the integrity of this serine is essential for this interaction in vitro.
In order to examine that issue in vivo, HeLa cells were transiently transfected to express both 14-3-3Z and a wild type or a mutant form of CDC25B3. After metabolic labelling with 35 S-methionine, CDC25B was immunoprecipitated to evidence the interaction with 14-3-3Z. Immunoprecipitation were performed using polyclonal antibodies raised against a CDC25B Figure 6 Ser-323 is essential for the interaction in vivo between CDC25B and 14-3-3Z. Asynchronous HeLa cells were transiently co-transfected to express wild type CDC25B3 or mutants (S323G and DN242-S323G) and 14-3-3Z. 24 h after transfection, metabolic labelling with 100 mCi/ml of 35 S-methionine/cystein was carried out for 3.5 h. Immunoprecipitations were performed using polyclonal antibodies against the carboxy-terminus of CDC25B. The samples were run on SDS-polyacrylamide gel electrophoresis prior to autoradiography. In vitro translated 35 S-methioninelabelled CDC25B3 and 14-3-3Z are shown in the three last lanes as migration control (arrows) Figure 7 Current working model for the interaction between CDC25B and 14-3-3 isoforms. (a) Interaction between CDC25B and two types of 14-3-3 protein is represented. Both types of isoform interact with a low anity binding site. Upon conformational changes that could occur after phosphorylation of CDC25B by an unknown kinase, or after binding of a regulatory partner, a speci®c interaction between CDC25B and 14-3-3Z and z isoforms is stabilized, while the low anity interaction is lost. (b) Removal of the amino terminal part of CDC25B (DN310) suppresses the low-anity binding site and abolishes binding of 14-3-3 proteins. However, the speci®c binding site for 14-3-3Z and z isoforms remains constitutively accessible (see text for more details) carboxy-terminal peptide. As shown in Figure 6 , 14-3-3Z was coimmunoprecipitated with wild type CDC25B. In contrast, the association of 14-3-3Z with S323G-CDC25B was barely detectable and was abolished with the DN242-S323G-CDC25B mutant. These results allow us to conclude that the integrity of serine 323 is also required in vivo for a signi®cant interaction with 14-3-3.
Discussion
The aim of this study was, on the basis of what was already known for CDC25C, to investigate the interaction between CDC25B phosphatases and members of the 14-3-3 protein family. Since we recently identi®ed three splice variants of the CDC25B phosphatase, we ®rst decided to examine whether these variant proteins were able to interact with 14-3-3 proteins. Our results with the two hybrid-assay as well as data obtained in vitro (not shown) clearly indicate that under our experimental conditions there was no detectable speci®city for a CDC25B variant. We next wished to examine the speci®city of the interaction of CDC25B with members of the 14-3-3 family. Since only restricted sets of 14-3-3 proteins had been used in most of the studies performed previously, we decided to examine the interaction of CDC25B with a larger panel of known mammalian 14-3-3 variants. Twohybrid vectors and MBP-14-3-3b, e, z, Z and y fusion proteins were constructed or generously provided. Using the two-hybrid assay in budding yeast, we were able to show that CDC25B can interact with all MBP-14-3-3 proteins, a result that is in agreement with the fact that 14-3-3b and e were recovered in a genetic screen based on this interaction (Conklin et al., 1995) . However, we already had evidence that the stringency of the interaction was not identical, 14-3-3z, Z and b being the strongest partners, with which interaction with CDC25B was still possible in the presence of high concentrations of 3AT. This observation is in contrast to the situation in Xenopus oocytes where the 14-3-3 e isoform is the one that interacts the best with CDC25C. Thus our results suggest the existence of a distinct speci®city in the association between CDC25 B and C phosphatases, and 14-3-3 isoforms.
Surprisingly, in vitro interaction assays using MBP-14-3-3 proteins and full-length CDC25B did not reveal these dierences but rather a similar low level of interaction with all six isoforms. However, the in vivo binding properties of 14-3-3 were reproduced in vitro when N-truncated mutants of CDC25B were used. Thus, enhanced binding of MBP-14-3-3 Z and z was observed upon deletion of the ®rst 242 amino-acids. It culminated with the removal of 310 residues but was completely abolished upon deletion of 323 residues. These results suggest that the high anity binding site(s) recognized by these two 14-3-3 isoforms is(are) located in the 310 ± 323 region. The most likely binding site is obviously the third consensus sequencè RS 323 PSMP' that encompasses the CDC25C homologue of Ser216. We propose that, under the conditions used in the in vitro binding assay, the full length CDC25B protein adopts a`closed' conformation that expose only low anity binding sites that are recognized by all six 14-3-3 isoforms. Deletion of the amino-terminal region of CDC25B is required to reveal the high anity site for 14-3-3, suggesting that this site be buried in the full-length conformation. Moreover, this high anity site appears to be speci®c for the interaction with 14-3-3z and Z isoforms. In contrast, the amino-terminal domain of CDC25B alone is not sucient to bind 14-3-3 proteins, suggesting that the low anity binding site we proposed is probably conformational and requires the overall protein structure.
We show that, surprisingly, neither phosphorylation by CHK1 nor dephosphorylation by l phosphatase modi®ed the level of interaction between 14-3-3Z and CDC25B on both low-and high-anity binding sites. This suggests that MBP-14-3-3 binding is not dependent on the phosphorylation state of both types of sites. However, mutation of Ser-323 to Gly fully abolished the interaction between CDC25B and 14-3-3Z, both in vitro and in vivo indicating that the integrity of this site is required independently of any phosphorylation. There are other examples in the literature of 14-3-3 binding that does not require phosphorylation (Petosa et al., 1998) . These results are in sharp contrast with what has been shown to be the case for CDC25C, which requires C-TAK1 or CHK1 phosphorylation for high anity binding of 14-3-3 on Ser216 (Kumagai et al., 1998b) . However, they are in agreement with the observation that in ®ssion yeast lacking both CDS1 and CHK1, CDC25 still associates with 14-3-3 proteins (Chen et al., 1999) . In addition, we noted that Ser323 mutation aects 14-3-3 binding only on the truncated CDC25B mutant, where this site is accessible, whereas it has no eect on the binding of the wild-type protein, thus reinforcing the notion that this site remains masked and unoccupied in the full-length molecule.
The observation that the in vitro binding properties of the DN310-CDC25B mutant to 14-3-3 isoforms are strictly comparable to what was found in the twohybrid assay with wild type CDC25B led us to propose that the structural rearrangements induced by the amino-terminal deletions probably mimic modi®cations to the full length protein that occur naturally in vivo.
We speculate (see model in Figure 7 ) that either a phosphorylation event or the interaction with a regulatory partner might generate conformational changes that reveal the high-anity 14-3-3 binding site. Our results indicate that, if a phosphorylation event is involved in this reorganization, we can almost certainly exclude the CHK1 kinase from this process. Therefore, the eect of other kinases on the interaction with 14-3-3 should now be examined. Alternatively, the only non-14-3-3 partner of CDC25 described to date is the B-type cyclin, which has been shown in vitro and in vivo to interact with and stimulate the activity of CDC25C (Galaktionov and Beach, 1991; Jessus and Beach, 1992; Zheng and Ruderman, 1993) . Whether such an interaction modi®es the accessibility for 14-3-3 binding remains to be investigated. Conversely, since we failed to demonstrate cyclin B association with wild-type CDC25B in vitro (data not shown), it is possible that the conformational changes of CDC25B that promote 14-3-3 binding are also required for interaction with cyclinB.
All together, our results suggest that the regulation of CDC25B and CDC25C diers in at least two aspects. First, both CDC25 phosphatases display binding speci®city for 14-3-3 isoforms. Pull-down assays showed that the Xenopus CDC25 is preferentially associated with the b, z and e isoforms (KumagaõÈ and Dunphy, 1999; Kumagai et al., 1998a, b; Yang et al., 1999) . In our study, CDC25B strongly associates with z and Z 14-3-3 isoforms and very weakly with e. However, these results were obtained through dierent technical approaches and may also be in¯uenced by the 14-3-3 composition of the Xenopus egg extract. Second, the association of CDC25B with 14-3-3 is not regulated by the classical phosphorylation/binding rule previously described in the case of CDC25C, and also for a number of other 14-3-3 ligands. One hypothesis is that phosphorylation of the 14-3-3 binding sequence is required for steric accessibility of the site rather than for direct tethering of 14-3-3 to CDC25B.
As mentioned in the introduction, 14-3-3 proteins have been proposed to act as adapter proteins. Recent studies indicate that the interaction between 14-3-3 and CDC25C is essential for the cytoplasmic localization of the phosphatase during interphase (Dalal et al., 1999; Kumagai and Dunphy, 1999) . It seems likely therefore that the interaction of CDC25 with 14-3-3 and the nuclear export machinery is tightly linked. Whether the intracellular localization of CDC25B is regulated in the same way should be examined. Interaction of the dierent CDC25 phosphatases with speci®c 14-3-3 isoforms would therefore be an additional mechanism controlling the cell cycle progression in response to the activation of various signalling pathways.
Materials and methods
Yeast and prokaryotic expression vectors
Human cDNA encoding the full length CDC25B1, B2 and B3 variants were cloned into NdeI ± BamHI sites in the pET14b vector (Novagen) as a NdeI ± BamHI-cut PCR product ampli®ed with the primers 5'-GTT ATT ATC ATA TG-G AGG TGC CCC AGC CG-3' (sense) and 5'-GAC GGA TTC GCT AGG GGG CCG AGC TG-3' (antisense) using Extrapol I Taq polymerase (Eurobio). The deletion mutants DN58, DN122, DN200, DN242, DN288, DN310 and DN323 were constructed, in the pET-14b vector, by subcloning of NdeI ± BamHI-cut PCR fragments ampli®ed with 5'-GTT ATT ATC ATA TGC ACG ACC TGCG C-3', 5'-GTT ATT ATC ATA TGG CGG AGC AGA CG-3', 5'-GTT ATT ATC ATA TGC CAT GGA AGC C-3', 5'-GTT ATT ATC ATA TGG AAG TGG AGG AG-3', 5'-GTT ATT ATC ATA TGG AGA GTC TCA TTA G-3', 5'-GTT ATT ATC ATA TGT ACA GCA AGT GC-3' sense primers and 5'-GAC GGA TCC GCT AGG GGG CCG AGC TG-3' antisense primer, respectively. A phosphorylation mutant on serine 323 of CDC25B3 was generated by PCR by SiteDirected Mutagenesis using the primer 5'-CTC TTC CGC TCC CCG GGC ATG CCC TGC AGC G-3' (sense) and 5'-CGC TGC AGG GCA TGC CCG GGG AGC G-GA AGA G-3' (antisense) using Pfu DNA polymerase (Promega).
CDC25B1, B2 and B3 cDNAs were puri®ed from pET plasmids by NdeI and BamHI digestion. The cohesive NdeI ends were made blunt by Klenow treatment and inserted directionally into SmaI and BamHI sites of the pGBT9 vector, in-frame with the GAL4-DNA binding domain. 14-3-3 cDNAs were cloned in frame with the Gal4 activating domain in the pGAD plasmids. pGADGH-14-3-3b was kindly provided by H Robertson. The pGBT9 and pGAD plasmids contained selection markers providing tryptophan or leucine prototrophy respectively.
14-3-3 cDNAs were isolated from the above described constructs and from pGEX14-3-3s vector kindly provided by M Yae. All cDNAs were then subcloned into compatible sites on pMALc2 plasmid in frame with the maltose binding domain. The pMALc2-14-3-3z plasmid was a generous gift of M Yasuda. The construction of the pcDNA 3 -HA-CDC25B3 wild type and mutants has been described elsewhere (Davezac, manuscript submitted). The pX-14-3-3Z was constructed by inserting the 14-3-3Z cDNA in the CMV drived pX vector (Superti-Furga et al., 1991) .
Yeast two-hybrid interaction assay pGBT9 and pGAD plasmids were co-transformed in the YGH1 budding yeast strain (Mata, , LYS : : GAL1UAS-gal1TATA-HIS3, URA3 : : gal1-LacZ). Transformants were selected on SD synthetic medium (yeast nitrogen base 6.7 g/l, D + Glucose 2%, Adenine 40 mg/l, Agar 20 g/l) supplemented with all essential amino-acids but leucine and tryptophan. Interaction between GAL4 fusion proteins was assessed by the activation of the His3 and LacZ reporter genes. To evaluate the stringency of these interactions, 2.10 4 cells of each clone were spotted on SD plates lacking leucine, tryptophan and histidine in the presence of increasing concentrations of 3-amino-triazol (a His3 competitor). Growth was evaluated after 60 h at 308C.
Production and purification of CHK1 kinase
Human CHK1 kinase was produced in the bacterial strain DH5a, using the pGEX-4T2 expression vector. The production of Gst-CHK1 fusion protein was induced with 0.4 mM isopropyl-b-thiogalactoside (IPTG) during 7 h at 258C. The recombinant protein was recovered as described by (Smith and Johnson, 1988) on glutathione-Sepharose beads, then eluted with 10 mM glutathione in 50 mM Tris-HCl, pH 8.
In vitro binding assay MBP-14-3-3 fusion proteins were produced in DH5a. Cells were recovered by centrifugation, sonicated in saline buer (10 mM Tris pH 7.5, 250 mM NaCl, 17 mg/ml PMSF, 10 mg/ ml trypsin inhibitor, 40 mg/ml TLCK, 80 mg/ml TPCK, 0.8 mg/ml leupeptin, 2 mg/ml aprotinin) and Tween 20 was added to the homogenate to a ®nal concentration of 0.1%. After a further 15 m incubation on ice, recombinant proteins were recovered in the 10 000 g supernatant.
CDC25B proteins were transcribed and translated in vitro using the TNT7 Quick kit (Promega) and pET expression plasmids encoding either wild type or mutated version of CDC25B, according to the instructions of the manufacturer.
For binding experiments, about 10 mg of the MBP-14-3-3 fusion protein were mixed with 3 ml of in vitro translated CDC25B in a 100 ml ®nal volume of kinase buer (50 mM Tris pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 1 mM ATP). In the experiments designed to examine the importance of CHK1 phosphorylation in the interaction, 6 mg of recombinant CHK1 kinase were further added to the reaction mixture. In all experiments, the amount of total protein was adjusted to 50 mg per tube with control bacterial lysate. Binding was allowed to proceed for 30 min at 308C and 14-3-3 proteins were then recovered by anity chromatography on amylose resin (Clontech) for 2 h at 48C in a low-stringency buer (20 mM Tris pH 7.5, 50 mM NaF, 1 mM DTT). After three washes in the recommended buer (20 mM Tris pH 7.5, 200 mM NaCl, 10 mM bME, 1 mM EDTA), the puri®ed MPB-14-3-3 were resolved on 12% polyacrylamide gels.
Association with 35 S-CDC25B was evidenced by autoradiography and measured by the PhosphorImager quanti®cation program.
Lambda phosphatase treatment
Following in vitro translation, 25 ml of reticulocyte lysate containing the CDC25B product were further incubated for 30 min at 308C in the absence or presence of 100 units of recombinant l phosphatase (New England Biolabs). The reaction was performed in a ®nal volume of 50 ml in the supplied buer supplemented to 50 mM Tris pH 7.5, 0.1 mM EDTA, 5 mM DTT, 0.01% Brij35 and 2 mM MnCl 2 , 6 ml of treated and control reticulocyte lysates were then used in the interaction assay as described above. For the experiment shown Figure 5a , in vitro translation was performed in the absence of [ 
Metabolic labelling and immunoprecipitation
For metabolic labelling, cells transiently transfected with pcDNA 3 -HA CDC25B3 and pX-14-3-3Z were pre-incubated 30 min in methionine and cysteine-free DMEM, followed by the addition of [ 35 S]methionine/cysteine (1000 Ci/mMole; Amersham) to a ®nal concentration of 100 mCi/ml for 3.5 h. Cells were lysed for 30 min at 48C, in lysis buer containing: 50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 5 mM EDTA, 0.1% Triton-X100, 1 mM DTT and protease and phosphatase inhibitors (Baldin et al., 1997) . Immunoprecipitations were performed using polyclonal antibodies raised against CDC25B. In vitro transcription and translation of CDC25B3 and 14-3-3Z were performed using the TNT quick system (Promega) in the presence of 35 S-methionine. Proteins were analysed by electrophoresis on SDS-12.5% polyacrylamide gels and autoradiography.
Abbreviations MBP, Maltose binding protein; CHK1, checkpoint kinase 1
